

## Integra LifeSciences Announces New Three-Year Agreement With Premier

## Premier Purchasing Partners Will Continue to Contract Jarit(R) Surgical and Laparoscopic Instruments

PLAINSBORO, N.J., Dec. 21, 2009 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has signed a new three-year contract for Jarit(R) surgical and laparoscopic instruments with Premier Purchasing Partners, LP, the group purchasing unit of one of the largest healthcare alliances in the United States.

"We are very excited that Premier has selected Integra as a contracted supplier of surgical instruments," said Debbie Leonetti, President, Integra Surgical. "This is our third contract with Premier and it reflects our continuing commitment to provide their members with the highest quality surgical instruments and service."

Jarit(R) instruments are used in virtually all surgical disciplines (i.e., neurosurgery, orthopedics, general surgery, plastic and reconstructive surgery, ear nose and throat, cardiovascular, obstetrics and gynecology, and ophthalmics) at more than 5,200 hospitals and surgery centers worldwide. Integra maintains one of the industry's most comprehensive surgical instruments inventory to ensure complete and timely delivery. With over 10,000 patterns available in a growing instrument portfolio, Integra can provide instruments quickly and economically. In its facility in Tuttlingen, Germany, Integra's staff manages supplier control, testing and quality system standards, which are ISO 13485: 2003 certified, and works directly with outstanding instrument craftsmen to coordinate design, production and delivery.

Integra's direct sales organization and distributor network sells Jarit(R) products. Integra Surgical is a leading provider of Jarit (R) brand surgical instruments, the Omni-Tract(R) family of retractor systems, and the Luxtec(R) illumination products. For more information, visit <u>www.integrasurgical.com</u>

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Integra's products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit <u>www.integra-ls.com</u>.

About Premier Inc., 2006 Malcolm Baldrige National Quality Award recipient

The Premier healthcare alliance is more than 2,200 U.S. hospitals and 63,000-plus other healthcare sites working together to improve healthcare quality and affordability. Owned by not-for-profit hospitals, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has offices in San Diego, Philadelphia and Washington.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra LifeSciences. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Luxtec(R) illumination products, Jarit(R) brand surgical instruments and Omni-Tract(R) retractor systems may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

## IART-P

CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella, Director of Corporate Communications (609) 936-2389 gsabella@integra-LS.com (C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.